Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Renal Cell Carcinoma (aRCC): early-phase trial registry
1 of 2 indexed Advanced Renal Cell Carcinoma (aRCC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Advanced Renal Cell Carcinoma (aRCC): 2 US clinical trials tracked, 1 recruiting.
Advanced Renal Cell Carcinoma (aRCC) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Brian Rini, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-renal-cell-carcinoma-arcc
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Advanced Renal Cell Carcinoma (aRCC) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Renal Cell Carcinoma (aRCC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Renal Cell Carcinoma (aRCC) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Brian Rini
NCT07188896
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Bristol-Myers Squibb
NCT06345183
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Renal Cell Carcinoma (aRCC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Renal Cell Carcinoma (aRCC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Renal Cell Carcinoma (aRCC) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Advanced Renal Cell Carcinoma (aRCC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Brian Rini sponsors the most Advanced Renal Cell Carcinoma (aRCC) trials on record, review their full trial history before evaluating a specific study. See Brian Rini's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Renal Cell Carcinoma (aRCC) condition card totals 2 registered trials; most-linked intervention Pembrolizumab + Lenvatinib combination therapy; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.